search
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • News
    • Events
    • Careers
  • Research & Pipeline
    • Paxalisib
    • Cantrixil
    • Collaborations
    • Publications & Presentations
  • Partnering
  • Investor Centre
    • ASX Announcements
    • SEC Filings
    • Company Reports
    • Company Meetings
    • Corporate Presentations
    • Analyst Reports
    • Investor Newsletters
    • Shareholder Services
    • COVID-19
    • Entitlement Offer
  • Media Centre
    • Video
    • Insights
MENU
  • Home
  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • News
    • Events
    • Careers
  • Research & Pipeline
    • Overview
    • Paxalisib
    • Cantrixil
    • Test
    • Collaborations
    • Publications & Presentations
  • Partnering
  • Investor Centre
    • Overview
    • ASX Announcements
    • SEC Filings
    • Company Reports
    • Company Meetings
    • Corporate Presentations
    • Analyst Reports
    • Investor Newsletters
    • Shareholder Services
    • COVID-19
    • Entitlement Offer
  • Media Centre
    • Video
    • Insights
  • CONTACT US
  • /
  • Media Centre
  • /
  • Insights
  • Media Centre
  • Overview
  • Video
  • Insights
  • 28-Sep-2020Media release

    CEO, Dr James Garner interviewed by Share Café on Dana Farber collaboration

    Our CEO, Dr James Garner recently conducted a video interview with Share Café following Kazia’s announcement of a collaboration with Dana-Farber Cancer Institute to investigate the use of paxalisib in primary central nervous system (CNS) lymphoma, a potential new indication for the drug.

    Read More

  • 26-Aug-2020Media release

    CEO, Dr James Garner interviewed on Share Café

    Our CEO, Dr James Garner recently conducted video and print interviews with Share Café following the US Food and Drug Administration’s award of Rare Pediatric Disease Designation for paxalisib in Diffuse Intrinsic Pontine Glioma (DIPG) and Fast Track Designation for paxalisib in glioblastoma.

    Read More

  • 18-Aug-2020Media release

    Leading Australian cancer researcher, Dr Matt Dun, interviewed on Channel 7’s Sunrise

    Our collaborator, Dr Matt Dun, and Kazia CEO, Dr James Garner, were interviewed on Channel 7’s Sunrise program on the development of paxalisib for Diffuse Intrinsic Pontine Glioma (DIPG) and the grant by the FDA of Rare Pediatric Disease Designation for paxalisib for the treatment of DIPG.

    Read More

  • 12-Aug-2020Media release

    Dr James Garner article in Equity magazine

    Our CEO, Dr James Garner recently had an article published in EQUITY magazine – the membership magazine for the Australian Shareholders Association.

    Read More

  • 22-Jul-2020Media release

    Kazia calls for greater awareness of one of the deadliest brain cancers in the US

    This Glioblastoma (GBM) Awareness Day, Australian oncology-focused biotech company, Kazia calls for greater awareness of one of the most lethal brain cancers in the US.

    Read More

  • 23-Jun-2020Media release

    Dr James Garner discusses paxalisib development with the Australian Shareholders Association

    Our CEO, Dr James Garner sat down with the Australian Shareholders Association to discuss the development of our lead candidate, paxalisib, for glioblastoma.

    Read More

  • 08-Jun-2020Media release

    World Brain Tumour Day: Kazia is urging awareness of the signs and symptoms of brain tumours

    On World Brain Tumour Day (June 8), Kazia is calling for greater awareness of the signs and symptoms of brain tumours, as they can often be malignant and therefore, a potentially deadly condition.

    Read More

  • 29-May-2020Media release

    World Ovarian Cancer Day: Encouraging all women to be aware of their family medical history

    As May draws to a close, we’d like to look back on World Ovarian Cancer Day, which was held on May 8.

    Read More

  • 27-Apr-2020Media release

    Dr James Garner discusses paxalisib data with FNN

    Our CEO, Dr James Garner recently conducted an interview with FNN which focused on the recent interim data from Kazia’s ongoing phase II trial of paxalisib in glioblastoma.

    Read More

  • 17-Mar-2020Media release

    March 2020 Shareholder Newsletter

    Kazia Therapeutics is pleased to make its March 2020 newsletter available to investors.

    Read More

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Subscribe to Insights

    Enter your email address to subscribe to our insights and receive notifications of new posts by email.

    Required values are marked



    Submit
  • SITE MAP
  • /
  • PRINT PAGE
  • /
  • TERMS OF USE
  • /
  • PRIVACY

  • FORWARD-LOOKING STATEMENTS
  • /
  • COOKIE POLICY
SITE BY SPATIAL DESIGN